You are here
FDA, Bayer Withdraw Sargramostim After Increased Reports of Adverse Events
The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation of liquid Leukine to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates has not been observed with the use of lyophilized Leukine. Healthcare professionals should immediately stop using liquid Leukine and return unused vials to the manufacturer.
View the 'Dear Healthcare Professional' letter: Click here.
Source: Food and Drug Administration